217 related articles for article (PubMed ID: 30936097)
21. Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Swanson RV; Ammerman NC; Ngcobo B; Adamson J; Moodley C; Dorasamy A; Moodley S; Mgaga Z; Bester LA; Singh SD; Almeida DV; Grosset JH
Antimicrob Agents Chemother; 2016 May; 60(5):2864-9. PubMed ID: 26926638
[TBL] [Abstract][Full Text] [Related]
22. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Miyazaki E; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Sep; 43(9):2126-30. PubMed ID: 10471552
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis.
Lanoix JP; Lenaerts AJ; Nuermberger EL
Dis Model Mech; 2015 Jun; 8(6):603-10. PubMed ID: 26035868
[TBL] [Abstract][Full Text] [Related]
24. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
[TBL] [Abstract][Full Text] [Related]
25. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
26. Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
Ammerman NC; Swanson RV; Bautista EM; Almeida DV; Saini V; Omansen TF; Guo H; Chang YS; Li SY; Tapley A; Tasneen R; Tyagi S; Betoudji F; Moodley C; Ngcobo B; Pillay L; Bester LA; Singh SD; Chaisson RE; Nuermberger E; Grosset JH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735562
[TBL] [Abstract][Full Text] [Related]
27. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
Irwin SM; Gruppo V; Brooks E; Gilliland J; Scherman M; Reichlen MJ; Leistikow R; Kramnik I; Nuermberger EL; Voskuil MI; Lenaerts AJ
Antimicrob Agents Chemother; 2014 Jul; 58(7):4026-34. PubMed ID: 24798275
[TBL] [Abstract][Full Text] [Related]
28. TB47 and clofazimine form a highly synergistic sterilizing block in a second-line regimen for tuberculosis in mice.
Yu W; Chiwala G; Gao Y; Liu Z; Sapkota S; Lu Z; Guo L; Khan SA; Zhong N; Zhang T
Biomed Pharmacother; 2020 Nov; 131():110782. PubMed ID: 33152940
[TBL] [Abstract][Full Text] [Related]
29. An update on the use of rifapentine for tuberculosis therapy.
Chan JG; Bai X; Traini D
Expert Opin Drug Deliv; 2014 Mar; 11(3):421-31. PubMed ID: 24397259
[TBL] [Abstract][Full Text] [Related]
30. Improving treatment outcome assessment in a mouse tuberculosis model.
Mourik BC; Svensson RJ; de Knegt GJ; Bax HI; Verbon A; Simonsson USH; de Steenwinkel JEM
Sci Rep; 2018 Apr; 8(1):5714. PubMed ID: 29632372
[TBL] [Abstract][Full Text] [Related]
31. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE; Nahid P; Kurbatova EV; Phillips PPJ; Bryant K; Dooley KE; Engle M; Goldberg SV; Phan HTT; Hakim J; Johnson JL; Lourens M; Martinson NA; Muzanyi G; Narunsky K; Nerette S; Nguyen NV; Pham TH; Pierre S; Purfield AE; Samaneka W; Savic RM; Sanne I; Scott NA; Shenje J; Sizemore E; Vernon A; Waja Z; Weiner M; Swindells S; Chaisson RE; ;
N Engl J Med; 2021 May; 384(18):1705-1718. PubMed ID: 33951360
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Andries K; Gevers T; Lounis N
Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
[TBL] [Abstract][Full Text] [Related]
33. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.
Grosset J; Lounis N; Truffot-Pernot C; O'Brien RJ; Raviglione MC; Ji B
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1436-40. PubMed ID: 9603120
[TBL] [Abstract][Full Text] [Related]
34. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
[TBL] [Abstract][Full Text] [Related]
35. Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
Cruz AT; Starke JR
Pediatr Infect Dis J; 2016 Jul; 35(7):811-3. PubMed ID: 27088582
[TBL] [Abstract][Full Text] [Related]
36. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
Harper J; Skerry C; Davis SL; Tasneen R; Weir M; Kramnik I; Bishai WR; Pomper MG; Nuermberger EL; Jain SK
J Infect Dis; 2012 Feb; 205(4):595-602. PubMed ID: 22198962
[TBL] [Abstract][Full Text] [Related]
37. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
[TBL] [Abstract][Full Text] [Related]
39. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
40. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ho CM; Horwitz MA
PLoS One; 2018; 13(11):e0207469. PubMed ID: 30427938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
